Sodium–glucose cotransporter type 2 inhibitors: managing the small but critical risk of diabetic ketoacidosis

Hamblin, Peter S; Wong, Rosemary; Bach, Leon A

doi:10.5694/mja2.50898

Topics

In reply: We thank Meyer and colleagues for their interest in our article. The risk of sodium–glucose cotransporter type 2 (SGLT2) inhibitor‐associated diabetic ketoacidosis in acutely unwell patients and people using ketogenic diets is already outlined in our article and does not require further comment.1

1 Western Health, Melbourne, VIC
2 University of Melbourne, Melbourne, VIC
3 Box Hill Hospital, Melbourne, VIC
4 Alfred Hospital, Melbourne, VIC
5 Monash University, Melbourne, VIC

Correspondence: peter.hamblin@wh.org.au

Competing interests:

No relevant disclosures.

1. Hamblin PS, Wong R, Bach LA. Sodium–glucose cotransporter type 2 inhibitors: managing the small but critical risk of diabetic ketoacidosis. Med J Aust 2020; 212: 294–296. https://www.mja.com.au/journal/2020/212/7/sodium-glucose-cotransporter-type-2-inhibitors-managing-small-critical-risk
2. Hamblin PS, Wong R, Ekinci EI, et al. SGLT2 inhibitors increase the risk of diabetic ketoacidosis developing in the community and during hospital admission. J Clin Endocrinol Metab 2019; 104: 3077–3087.
3. Australian Diabetes Society. Alert update: periprocedural diabetic ketoacidosis (DKA) with SGLT2 inhibitor use. January 2020. http://diabetessociety.com.au/documents/ADS_DKA_SGLT2i_Alert_update_2020.pdf (viewed Nov 2020).

Online responses are no longer available. Please refer to our instructions for authors page for more information.